Eyeworld Supplements

Pipeline, Products and Promise Promise T o deliver on a promise of developing innovative specialty medicines in therapeutic areas of both unmet patient and physician needs, Shire recognizes the importance of building strong and sustainable relationships with professional and advocacy organizations. Through regular and open dia- logue, Shire aims to better understand and address the needs of the entire eyecare community. To learn more about Shire's philosophy and commitment, visit www.shire-eyes.com. 1. Shire is committed to working with organizations that further education around eye health, for example the Tear Film & Ocular Surface Society (TFOS). Shire currently sits on the TFOS Corporate Advisory Board and is a Platinum Sponsor of its DEWS II Workshop. 2. Shire is committed to working with patient groups like the Foundation Fighting Blindness (FFB) to raise awareness, support education and research, and enhance the dialogue between patients and eyecare profes- sionals. In 2015, Shire announced a research agreement with the FFB to further research for a novel treatment for autosomal dominant retinitis pigmentosa, for which there are no current- ly approved treatment options. 3. The company has established relationships with professional organizations representing ophthal- mologists, optometrists, opticians, and technicians, such as the American Academy of Ophthalmology (AAO), the American Academy of Optometry (AAOpt), Ophthalmic Wom- en Leaders (OWL), and the Joint Commission on Allied Health Personnel in Ophthalmology (JCAHPO). 4. In addition, since 2014, Shire has had a presence at the major eye health medical meetings, includ- ing Royal Hawaiian Eye, South Eastern Congress of Optometry (SECO), American Society of Cataract & Refractive Surgery (ASCRS), Ophthalmic Imaging Association (OIA), Association for Research in Vision and Ophthalmology (ARVO), American Optometric Association (AOA), AAO, and AAOpt. By attending these meetings to engage with the spectrum of eyecare professionals, Shire is learning where there are areas of the greatest unmet need, and how best to focus its efforts on addressing those gaps in care. Pipeline and products O phthalmics is a global pharmaceutical market with significant unmet medical need in both front of the eye and back of the eye conditions. Retinal degenera- tive diseases, glaucoma, and dry eye are diseases that affect millions globally and represent an opportunity for innovative treatments. Ophthalmics is an area that aligns with Shire's existing focus on specialty conditions as well as its expertise in developing and commercializing therapeutics for rare diseases. The growth of Shire in Ophthalmics has been driven by a combination of strategic acquisitions and organic growth. Recent acquisitions of Foresight Biotherapeutics, SARcode Bioscience, Premacure AB, and BIKAM Pharmaceuticals mark a solid demonstration of the company's commitment to ophthalmics and to advancing investigational candidates at all stages of development. As a result, the company currently has an Ophthalmics pipeline of investigational products at various stages of de- velopment, including in dry eye, infectious conjunctivitis, retinopathy of prematurity, autosomal dominant retinitis pigmentosa, and glaucoma. Shire's Ophthalmics pipeline as of September 2015 S07705 1/16 Dry eye disease Infectious conjunctivitis Autosomal dominant retinitis pigmentosa Glaucoma Preclinical Phase 1 Phase 2 Phase 3 Retinopathy of prematurity 4

• Cover